CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 145 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $262,000 | +26100.0% | 77,403 | +184192.9% | 0.00% | – |
| Q3 2021 | $1,000 | -50.0% | 42 | -92.0% | 0.00% | – |
| Q2 2021 | $2,000 | -50.0% | 523 | -36.9% | 0.00% | – |
| Q1 2021 | $4,000 | +100.0% | 829 | +155.1% | 0.00% | – |
| Q4 2020 | $2,000 | -33.3% | 325 | -6.9% | 0.00% | – |
| Q3 2020 | $3,000 | +50.0% | 349 | -32.5% | 0.00% | – |
| Q2 2020 | $2,000 | -98.9% | 517 | -99.6% | 0.00% | -100.0% |
| Q1 2020 | $185,000 | -4.1% | 125,039 | +26.8% | 0.00% | – |
| Q4 2019 | $193,000 | +3.8% | 98,588 | +170.8% | 0.00% | – |
| Q3 2019 | $186,000 | +675.0% | 36,403 | +998.1% | 0.00% | – |
| Q2 2019 | $24,000 | +300.0% | 3,315 | +667.4% | 0.00% | – |
| Q1 2019 | $6,000 | +200.0% | 432 | +151.2% | 0.00% | – |
| Q1 2018 | $2,000 | -85.7% | 172 | -92.8% | 0.00% | – |
| Q2 2017 | $14,000 | +55.6% | 2,393 | +12.8% | 0.00% | – |
| Q1 2017 | $9,000 | – | 2,121 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |